11 Good Energy, Inc. ELVN 深 沪
等待开盘 10-10 09:30:00 美东时间
21.42
+1.100
+5.41%
华盛通- 最 高21.81
- 今 开20.30
- 成交量 73.21万股
- 最 低 20.24
- 昨 收 20.32
- 总市值 10.51亿
- 52周最高 29.785
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.30
- 委 比 54.59%
- 总股本 4906.93万
- 历史最高 250.84
- 量 比 2.46
- 振 幅 7.73%
- 历史最低 3.896
- 每 手 1
- 风险率 3.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enliven Therapeutics Q2 EPS $(0.49) Beats $(0.54) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.54) by 9.26 percent. This is a 19.51 percent decrease over losses of $(0.41) per share
08-14 04:25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-18 21:30
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $40 to $48.
07-02 18:47
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
Enliven Therapeutics Announces Public Offering Agreement
An announcement from Enliven Therapeutics ( ($ELVN) ) is now available. On June...
06-16 18:58
Enliven Therapeutics Launches $200M Public Offering With Option For $30M Upsize
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced
06-13 18:16
Enliven Therapeutics Announced Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With Chronic Myeloid Leukemia In An Oral Presentation At European Hematology Association 2025 Congress
Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achievingMMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved
06-13 18:06
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
